{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:35:35Z","timestamp":1773365735195,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T00:00:00Z","timestamp":1272412800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s11926-010-0099-9","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T04:35:37Z","timestamp":1272342937000},"page":"163-169","source":"Crossref","is-referenced-by-count":17,"title":["Bone Changes and Fracture Risk in Individuals Infected With HIV"],"prefix":"10.1007","volume":"12","author":[{"given":"Amy H.","family":"Warriner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Mugavero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,28]]},"reference":[{"key":"99_CR1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1210\/jc.2003-031506","volume":"89","author":"TT Brown","year":"2004","unstructured":"Brown TT, Ruppe MD, Kassner R, et al.: Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004, 89:1200\u20131206.","journal-title":"J Clin Endocrinol Metab"},{"key":"99_CR2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/00002030-200309050-00010","volume":"17","author":"D Bruera","year":"2003","unstructured":"Bruera D, Luna N, David DO, et al.: Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003, 17:1917\u20131923.","journal-title":"AIDS"},{"key":"99_CR3","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/367569","volume":"36","author":"K Mondy","year":"2003","unstructured":"Mondy K, Yarasheski K, Powderly WG, et al.: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus\u2013infected individuals. Clin Infect Dis 2003, 36:482\u2013490.","journal-title":"Clin Infect Dis"},{"key":"99_CR4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/00002030-200107060-00009","volume":"15","author":"D Nolan","year":"2001","unstructured":"Nolan D, Upton R, McKinnon E, et al.: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15:1275\u20131280.","journal-title":"AIDS"},{"key":"99_CR5","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-200003100-00005","volume":"14","author":"P Tebas","year":"2000","unstructured":"Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63\u2013F67.","journal-title":"AIDS"},{"key":"99_CR6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00198-007-0428-7","volume":"18","author":"J Prior","year":"2007","unstructured":"Prior J, Burdge D, Maan E, et al.: Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007, 18:1345\u20131353.","journal-title":"Osteoporos Int"},{"key":"99_CR7","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1210\/jc.2008-0828","volume":"93","author":"VA Triant","year":"2008","unstructured":"\u2022\u2022 Triant VA, Brown TT, Lee H, Grinspoon SK: Fracture prevalence among human immunodeficiency virus (HIV)\u2013infected versus non\u2013HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008, 93:3499\u20133504. This study provides an estimate of fracture occurrence in HIV-infected individuals compared with non\u2013HIV-infected individuals within a large US hospital database. Evidence from the study supports the notion that HIV-positive individuals are at increased risk of fracture.","journal-title":"J Clin Endocrinol Metab"},{"key":"99_CR8","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","volume":"20","author":"TT Brown","year":"2006","unstructured":"Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165\u20132174.","journal-title":"AIDS"},{"key":"99_CR9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1086\/341489","volume":"35","author":"MP Dub\u00e9","year":"2002","unstructured":"Dub\u00e9 MP, Qian D, Edmondson-Melancon H, et al.: Prospective, intensive study of metabolic changes associated with 48\u00a0weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002, 35:475\u2013481.","journal-title":"Clin Infect Dis"},{"key":"99_CR10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00198-007-0524-8","volume":"19","author":"S Jones","year":"2008","unstructured":"Jones S, Restrepo D, Kasowitz A, et al.: Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008, 19:913\u2013918.","journal-title":"Osteoporos Int"},{"key":"99_CR11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","volume":"51","author":"TT Brown","year":"2009","unstructured":"Brown TT, McComsey GA, King MS, et al.: Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 51:554\u2013561.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"99_CR12","unstructured":"Overton ET, Mondy K, Bush T, et al.: Factors associated with low bone mineral density in a large cohort of HIV-infected US adults: baseline results from the SUN study [abstract]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25\u201328, 2007."},{"key":"99_CR13","first-page":"145","volume":"84","author":"P Aukrust","year":"1999","unstructured":"Aukrust P, Haug CJ, Ueland T, et al.: Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145\u2013150.","journal-title":"J Clin Endocrinol Metab"},{"key":"99_CR14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0083-6729(08)60407-0","volume":"52","author":"M Alsina","year":"1996","unstructured":"Alsina M, Guise TA, Roodman GD: Cytokine regulation of bone cell differentiation. Vitam Horm 1996, 52:63\u201398.","journal-title":"Vitam Horm"},{"key":"99_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1043-4666(03)00106-6","volume":"22","author":"S Abbas","year":"2003","unstructured":"Abbas S, Zhang YH, Clohisy JC, Abu-Amer Y: Tumor necrosis factor-alpha inhibits pre-osteoblast differentiation through its type-1 receptor. Cytokine 2003, 22:33\u201341.","journal-title":"Cytokine"},{"key":"99_CR16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bbrc.2004.11.077","volume":"328","author":"HC Blair","year":"2005","unstructured":"Blair HC, Robinson LJ, Zaidi M. Osteoclast signalling pathways. Biochem Biophys Res Commun 2005, 328:728\u2013738.","journal-title":"Biochem Biophys Res Commun"},{"key":"99_CR17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2174\/1381612013397807","volume":"7","author":"PJ Kostenuik","year":"2001","unstructured":"Kostenuik PJ, Shalhoub V: Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001, 7:613\u2013635.","journal-title":"Curr Pharm Des"},{"key":"99_CR18","first-page":"15","volume":"10","author":"L Nguyen","year":"1991","unstructured":"Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P: Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 1991, 10:15\u201321.","journal-title":"Lymphokine Cytokine Res"},{"key":"99_CR19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF01534268","volume":"18","author":"FS Panagakos","year":"1994","unstructured":"Panagakos FS, Hinojosa LP, Kumar S: Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factor-alpha. Inflammation 1994, 18:267\u2013284.","journal-title":"Inflammation"},{"key":"99_CR20","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1016\/8756-3282(95)00180-L","volume":"17","author":"SC Manolagas","year":"1995","unstructured":"Manolagas SC: Role of cytokines in bone resorption. Bone 1995, 17:63S\u201367S.","journal-title":"Bone"},{"issue":"Suppl 1","key":"99_CR21","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1007\/BF01673412","volume":"53","author":"GD Roodman","year":"1993","unstructured":"Roodman GD: Role of cytokines in the regulation of bone resorption. Calcif Tissue Int 1993, 53(Suppl 1):S94\u2013S98.","journal-title":"Calcif Tissue Int"},{"key":"99_CR22","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/jmv.21266","volume":"80","author":"D Gibellini","year":"2008","unstructured":"Gibellini D, De Crignis E, Ponti C, et al.: HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008, 80:1507\u20131514.","journal-title":"J Med Virol"},{"key":"99_CR23","doi-asserted-by":"crossref","first-page":"48251","DOI":"10.1074\/jbc.M304676200","volume":"278","author":"JM Fakruddin","year":"2003","unstructured":"Fakruddin JM, Laurence J: HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma\/RANKL cross-talk. J Biol Chem 2003, 278:48251\u201348258.","journal-title":"J Biol Chem"},{"key":"99_CR24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2249.2004.02568.x","volume":"137","author":"JM Fakruddin","year":"2004","unstructured":"Fakruddin JM, Laurence J: Interactions among human immunodeficiency virus (HIV)-1, interferon-gamma and receptor of activated NF-kappa B ligand (RANKL): implications for HIV pathogenesis. Clin Exp Immunol 2004, 137:538\u2013545.","journal-title":"Clin Exp Immunol"},{"key":"99_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00705-004-0395-7","volume":"150","author":"JM Fakruddin","year":"2005","unstructured":"Fakruddin JM, Laurence J: HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005, 150:67\u201378.","journal-title":"Arch Virol"},{"key":"99_CR26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1089\/aid.2007.0112","volume":"23","author":"EJ Cotter","year":"2007","unstructured":"Cotter EJ, Malizia AP, Chew N, et al.: HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007, 23:1521\u20131530.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"99_CR27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2474-9-33","volume":"9","author":"EJ Cotter","year":"2008","unstructured":"Cotter EJ, Ip HS, Powderly WG, Doran PP: Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskelet Disord 2008, 9:33.","journal-title":"BMC Musculoskelet Disord"},{"key":"99_CR28","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/QAD.0b013e32832c1792","volume":"23","author":"B Grund","year":"2009","unstructured":"Grund B, Peng G, Gibert CL, et al.: Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009, 23:1519\u20131529.","journal-title":"AIDS"},{"key":"99_CR29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2265.2007.02875.x","volume":"67","author":"MJ Bolland","year":"2007","unstructured":"Bolland MJ, Grey AB, Horne AM, et al.: Bone mineral density remains stable in HAART-treated HIV-infected men over 2\u00a0years. Clin Endocrinol (Oxf) 2007, 67:270\u2013275.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"99_CR30","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1210\/jc.2006-0127","volume":"91","author":"SE Dolan","year":"2006","unstructured":"Dolan SE, Kanter JR, Grinspoon S: Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006, 91:2938\u20132945.","journal-title":"J Clin Endocrinol Metab"},{"key":"99_CR31","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/QAD.0b013e328328f789","volume":"23","author":"C Duvivier","year":"2009","unstructured":"Duvivier C, Kolta S, Assoumou L, et al.: Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009, 23:817\u2013824.","journal-title":"AIDS"},{"key":"99_CR32","unstructured":"Fakruddin JM, Yin M, Laurence J: Pathophysiologic correlates of RANKL deregulation in HIV infection and its therapy [abstract]. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22\u201325, 2005."},{"key":"99_CR33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","volume":"10","author":"CL Woodward","year":"2009","unstructured":"Woodward CL, Hall AM, Williams IG, et al.: Tenofovir-associated renal and bone toxicity. HIV Med 2009, 10:482\u2013487.","journal-title":"HIV Med"},{"key":"99_CR34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jpeds.2007.12.020","volume":"152","author":"JB Purdy","year":"2008","unstructured":"Purdy JB, Gafni RI, Reynolds JC, et al.: Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008, 152:582\u2013584.","journal-title":"J Pediatr"},{"key":"99_CR35","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","volume":"49","author":"A Martin","year":"2009","unstructured":"Martin A, Bloch M, Amin J, et al.: Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009, 49:1591\u20131601.","journal-title":"Clin Infect Dis"},{"key":"99_CR36","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1089\/aid.2006.22.1131","volume":"22","author":"G Pan","year":"2006","unstructured":"Pan G, Kilby M, McDonald JM: Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2006, 22:1131\u20131141.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"99_CR37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/0889222041217374","volume":"20","author":"P Tebas","year":"2004","unstructured":"Tebas P, Yarasheski K, Henry K, et al.: Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004, 20:589\u2013594.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"99_CR38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"JE Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191\u2013201.","journal-title":"JAMA"},{"key":"99_CR39","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1089\/aid.2008.0058","volume":"24","author":"CJ Bout-Van Den Beukel Van Den","year":"2008","unstructured":"Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24:1375\u20131382.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"99_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/aid.2008.0183","volume":"25","author":"M Rodr\u00eeguez","year":"2009","unstructured":"Rodr\u00eeguez M, Daniels B, Gunawardene S, Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009, 25:9\u201314.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"99_CR41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/infdis\/169.4.889","volume":"169","author":"C Haug","year":"1994","unstructured":"Haug C, Muller F, Aukrust P, Froland SS: Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis 1994, 169:889\u2013893.","journal-title":"J Infect Dis"},{"key":"99_CR42","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1210\/jcem.83.11.5270","volume":"83","author":"CJ Haug","year":"1998","unstructured":"Haug CJ, Aukrust P, Haug E, et al.: Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998, 83:3832\u20133838.","journal-title":"J Clin Endocrinol Metab"},{"key":"99_CR43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/00002030-200303070-00006","volume":"17","author":"M Cozzolino","year":"2003","unstructured":"Cozzolino M, Vidal M, Arcidiacono MV, et al.: HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003, 17:513\u2013520.","journal-title":"AIDS"},{"key":"99_CR44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1753-4887.2006.tb00205.x","volume":"64","author":"E Villamor","year":"2006","unstructured":"Villamor E: A potential role for vitamin D on HIV infection? Nutr Rev 2006, 64:226\u2013233.","journal-title":"Nutr Rev"},{"key":"99_CR45","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QAD.0b013e3280148c05","volume":"21","author":"JH Arnsten","year":"2007","unstructured":"Arnsten JH, Freeman R, Howard AA, et al.: Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007, 21:617\u2013623.","journal-title":"AIDS"},{"key":"99_CR46","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.qai.0000145352.04440.1e","volume":"38","author":"K Mondy","year":"2005","unstructured":"Mondy K, Powderly WG, Claxton SA, et al.: Alendronate, vitamin D, and calcium for the treatment of osteopenia\/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005, 38:426\u2013431.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"99_CR47","first-page":"343","volume":"19","author":"E Negredo","year":"2005","unstructured":"Negredo E, Martinez-L\u00f3pez E, Paredes R, et al.: Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS 2005, 19:343\u2013345.","journal-title":"AIDS"},{"key":"99_CR48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1310\/MD8V-5DLG-EN3T-BRHX","volume":"5","author":"G Guaraldi","year":"2004","unstructured":"Guaraldi G, Orlando G, Madeddu G, et al.: Alendronate reduces bone resorption in HIV-associated osteopenia\/osteoporosis. HIV Clin Trials 2004, 5:269\u2013277.","journal-title":"HIV Clin Trials"},{"key":"99_CR49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/QAD.0b013e32831c8adc","volume":"23","author":"J Huang","year":"2009","unstructured":"\u2022 Huang J, Meixner L, Fernandez S, McCutchan JA: A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009, 23:51\u201357. This study highlights the beneficial effect of bisphosphonate therapy in HIV-positive individuals with loss of BMD who are at risk of fracture.","journal-title":"AIDS"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0099-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-010-0099-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-010-0099-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:49:53Z","timestamp":1559436593000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-010-0099-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,28]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s11926-010-0099-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,28]]}}}